SCHEMBL30065513

SCHEMBL30065513

CC(C)(C)OC(=O)N[C@H]1CCCC[C@@H]1NS(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.46
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
MMP1 P03956 2/20 0.41
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
MMP8 P22894 2/20 0.41
MMP13 P45452 2/20 0.41
CA12 O43570 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9116923 0.86 ALDH1A1 (0.50) MAOAMAOBPOLBMMP13ALDH1A1
SCHEMBL4367542 0.86 ALDH1A1 (0.50) MAOAMAOBPOLBMMP13ALDH1A1
SCHEMBL4401404 0.84 TSHR (0.48) MAOAMAOBMEN1KMT2APOLB
SCHEMBL22084631 0.83 ALOX5 (0.47) ALOX5MAOAMAOBMEN1KMT2A
SCHEMBL23912288 0.82 DRD2 (0.51) ALOX5MAOAMAOBMEN1KMT2A
SCHEMBL21994368 0.82 MEN1 (0.48) MEN1KMT2APOLBTDP1CA1
SCHEMBL22084633 0.81 ALOX5 (0.47) ALOX5MAOAMAOBMEN1KMT2A
SCHEMBL22084059 0.81 ALOX5 (0.47) ALOX5MAOAMAOBMEN1KMT2A
SCHEMBL30221947 0.80 MEN1 (0.59) MEN1KMT2APOLBTDP1CA1
SCHEMBL7831193 0.78 SIGMAR1 (0.44) ALOX5KMT2ATDP1MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605451-B2 Targeted plasma protein degradation NOVARTIS AG (CH) 2026-04-21 US disclosed
US-20230398224-A1 TARGETED PLASMA PROTEIN DEGRADATION NOVARTIS AG (CH) 2023-12-14 US disclosed
US-20230089867-A1 CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER NOVARTIS AG (CH) 2023-03-23 US disclosed
EP-4100064-A1 TARGETED PLASMA PROTEIN DEGRADATION Novartis AG (CH) 2022-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605451-B2 Targeted plasma protein degradation M6PR, ASGR1, IGF2R ALOX5 4351/4885MAOA 1157/4885MAOB 858/4885
US-20230089867-A1 CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER PCSK9, PCSK7, PCSK6 ALOX5 1710/4885MAOA 2275/4885MAOB 1789/4885
US-20230398224-A1 TARGETED PLASMA PROTEIN DEGRADATION M6PR, ASGR1, IGF2R ALOX5 3884/4885MAOA 2183/4885MAOB 2616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.